Please join IDEAYA Biosciences for an R&D Day in London where management and key opinion leader Frank McCormick, Ph.D., of the UCSF Helen Diller Family Comprehensive Cancer Center, will outline the company’s current clinical development strategy in MTAP/CDKN2A and KRAS solid tumors, with a particular focus on pancreatic cancer (PDAC).

The event will include new preclinical data and perspectives on rational combination strategies IDEAYA is conducting to target the tumor heterogeneity and adaptive plasticity in PDAC and other priority solid tumor indications.

More detailed information on the agenda and speakers will be provided closer to the event.